Rainer Machauer
Novartis (Switzerland)(CH)Novartis (China)(CN)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Computational Drug Discovery Methods, Chemical Synthesis and Analysis, Cholinesterase and Neurodegenerative Diseases, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → The BACE ‐1 inhibitor CNP 520 for prevention trials in Alzheimer's disease(2018)169 cited
- → A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice(2015)109 cited
- → Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides(2012)98 cited
- → JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors(2022)90 cited
- → Enantioselective synthesis of (+)-anatoxin-a via enyne metathesis(2004)73 cited
- → Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice(2016)66 cited
- → Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach(2016)62 cited
- → Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application(2009)58 cited
- → Macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors with activity in vivo(2009)54 cited
- → Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach(2017)49 cited